Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 7 Ovarian Neoplasms 4 Stomach Neoplasms 3 Neoplasm Metastasis 3 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms 2 Multiple Myeloma 2 Lymphoma 2 Endometrial Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Recurrence 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Neoplasms, Unknown Primary 1 Mouth Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Laryngeal Neoplasms 1 Hypopharyngeal Neoplasms 1 Hematologic Neoplasms 1 Glioma 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Esophageal Neoplasms 1

Interventions

Oxaliplatin 26 Gemcitabine 22 Fluorouracil 17 Capecitabine 16 Leucovorin 15 pembrolizumab 14 Docetaxel 14 Cisplatin 13 Bevacizumab 12 Radiotherapy 8 Paclitaxel 8 Irinotecan 8 Trastuzumab 7 Pemetrexed 6 Carboplatin 6 130-nm albumin-bound paclitaxel 6 durvalumab 5 cemiplimab 5 Erlotinib Hydrochloride 5 Sunitinib 4 Ramucirumab 4 Metformin 4 Gefitinib 4 trastuzumab deruxtecan 3 tislelizumab 3 cabozantinib 3 atezolizumab 3 Taxes 3 Sorafenib 3 Panitumumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Adenocarcinoma × ipatasertib × Clear all

NCT04739202 2026-06-09

IMMUNOGAST

Hospices Civils de Lyon

Phase 2 Completed

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡